Archives of Clinical and Biomedical Research
EISSN : 2572-5017
Current Publisher: Fortune Journals (10.26502)
Total articles ≅ 110
Latest articles in this journal
Archives of Clinical and Biomedical Research; doi:10.26502/acbr
Archives of Clinical and Biomedical Research aims to get good Impact factor, indexing in SCI, Scopus, PubMed, ESCI, Clarivate Analytics, PMC, biomedical research journals
Archives of Clinical and Biomedical Research, Volume 4, pp 145-152; doi:10.26502/acbr.50170094
Introduction: Laparoscopic sleeve gastrectomy (SG) is an effective method for the treatment of obesity. Leakage is the most common and unfavorable complication of SG. Use of self-expandable metal stents (SEMS) has become the gold standard management. Aortoesophageal fistula (AEF) is a rare and life-threatening complication that can result from SEMS placement. Case Presentation: A 52 year old woman underwent laparoscopic SG for morbid obesity. Eight days after an esophagogastric SEMS placement was required for gastric leakage. Twenty two days later she presented massive hematemesis and active AEF was diagnosed requiring endovascular placement of thoracic endoprosthesis. SG conversion into Roux en Y gastric bypass (RYGB) with double pigtail stent placement was necessary for the persistence of gastric fistula. 45 days after, EGD revealed the aortic prosthesis at the distal portion of esophagus. For this reason, she underwent a thoracic aorta reconstruction and an esophago jejunal anastomosis. Discussion: Esophageal ulceration is a possible complication of SEMS placement and can lead to an AEF. In order to promptly identify and treat rare and fatal complications as AEF, it is important to always keep a high index of suspicion. Conclusion: The awareness of rare complications as AEF after SEMS placement is important in order to facilitate immediate surgical treatment and to raise survival possibility. It is important to be familiar with all different treatment options, as well as being updated on the latest Guidelines. A good knowledge of timing and best treatment option, depending on the leak and patient clinical status, are mandatories.
Archives of Clinical and Biomedical Research, Volume 4, pp 292-301; doi:10.26502/acbr.50170105
Introduction: This study’s aim was to evaluate the effects of irrigating solutions with 2% chlorhexidine gluconate (CHX) 17% ethylenediaminetetraacetic acid (EDTA), and 2.5% sodium hypochlorite (NaOCl) on root dentin microhardness. Methods: Eighty mesiobuccal canals from lower molars were irrigated with conventional irrigation(CI) or passive ultrasonic irrigation (PUI). The roots were divided into eight groups: CHX+CI; CHX+PUI; EDTA+CI; EDTA+PUI; NaOCl+CI; NaOCl+PUI; distilled water (DW)+CI; DW+PUI. The Knoop microhardness test was used to evaluate indentations at 100 μm and 500 μm in the cervical, middle and apical thirds. The results were analyzed with the Kruskal-Wallis (Dunn) test. Results: At 100 μm in the cervical third, the highest and lowest values were found in the CHX+PUI Group and EDTA+PUI groups, respectively (P
Archives of Clinical and Biomedical Research, Volume 4, pp 195-204; doi:10.26502/acbr.50170098
Purpose: Osteogenesis Imperfecta (OI) is a congenital disorder characterized by multiple fractures and a low bone mineral density (BMD). In our national OI expertise center for adults, we observed several cases of transient osteoporosis of the hip (TOH). The aim of this study was to report on the prevalence of TOH in adult OI patients, to identify possible additional risk factors and describe the natural history. Methods: The charts of 314 adult OI patients, seen on an outpatient base between January 2008 and January 2018, were reviewed for pain in the hip region. On the basis of pain with no reported trauma a Magnetic Resonance Imaging (MRI) was performed to identify patients with TOH and exclude other diseases. Additional risk factors were evaluated. Results: 5 of 314 (1.6%; 95% confidence interval 0.6% - 3.9%) OI patients showed TOH. There was a delay of 4-12 weeks between the start of the symptoms and the diagnosis of TOH. No additional risk factors were designated besides OI. Good clinical result by partial weight bearing in 4 patients, one patient received a total hip arthroplasty in a hospital in the surroundings of the patient. Conclusions: The prevalence of TOH in adult OIpatients is 1.6% in a ten years cohort. Due to the high prevalence, we recommend a MRI in OI-patients with pain in the hip region suspicious of TOH and inconclusive radiographs. No additional risk factors were noticed in our patient population for the development of TOH. The natural history is favorable by off-loading of the hip during the period of pain. We hypothesize that a mild degree of trauma causing microfractures could be the reason for bone marrow edema matching the clinical entity of TOH.
Archives of Clinical and Biomedical Research, Volume 4, pp 169-183; doi:10.26502/acbr.50170096
The development of allergy is partly dependent on changes in individual’s microbiota which were interacted with the environment. Microbiota can be modulated by early-life microbial exposures, diet, antibiotics. Lower microbial diversity is pivotal factor in developing diseases. Certain types of microorganisms are involved in a disease activity. Early life exposure to non-pathogenic Proteobacteria has a protective effects in developing allergies. Later, bacterias, involving Staphylococcus aureus (S.aureus) in the skin or pathogenic Proteobacteria in the airway, affects patients with atopic dermatitis (AD) and bronchial asthma (BA) respectively. Similarly Acinetobacteria in early exposure protectively effect BA. The pathogenic role of Proteobacteria phylum might differ between bronchial and skin inflammation. The microbiota at local sites is also involved in the development and activity of diseases in remote organs via‘triangular cross talk’. Cross talk among skin, air way, and gut is not surprising, because they are the superficial organs. Lactobacilus in the Firmicutis phylum always protectively work for allergic diseases of skin and bronchus. Therefore probiotics, which mature the gut barrier and prime the immune function, are currently being used to prevent and treat AD and BA. The accumulated data, however, have failed to substantiate fully the effects of probiotics against allergic disorders.
Archives of Clinical and Biomedical Research, Volume 4; doi:10.26502/acbr.50170085
Archives of Clinical and Biomedical Research, Volume 4, pp 33-47; doi:10.26502/acbr.50170087
Introduction: Polyunsaturated fatty acids (PUFA) supplementation is thought to reduce inflammation in cystic fibrosis. Likewise vitamin D has immunoregulatory properties. The aim of the study was to compare the effect of cholecalciferol supplementation to cholecalciferol with omega-3 supplementation on the inflammatory response of CF patients infected with P.aeruginosa. Methods: This was a double-blind, cross-over trial. Twenty-three CF patients (aged 6 – 19) infected by P. aeruginosa were randomised to received: cholecalciferol 1000IU or cholecalciferol 1000IU and omega – 3 1000 mg daily for three months. The levels of IL-23 and IL-17A in the exhaled breath condensate (EBC), calcium-phosphorus balance and serum lipid balance were measured. Data were analysed using means of Stata/Special Edition, release 14.2. Results: The level of IL-23 in EBC significantly decreased in vitamin D + omega-3 group from 9,39 pg/mL (± SD = 6,40 pg/mL) to 7,33 pg/mL (± SD = 3,88 pg/mL) (p = 0.023); there was no change in vitamin D group (p = 0.630). The blood concentration of 25OHD significantly increased in both groups: in vitamin D group form 24,64 ng/mL (± SD = 8,31 ng/mL) to 29,41 ng/mL (± SD = 7,78 ng/mL) (P < 0,001) and in vitamin D +omega-3 group from 24,31 ng/mL (± SD = 8,28 ng/mL) to 30,67 ng/mL (± SD = 8,01 ng/mL) (P < 0,001). Conclusions: Omega-3 supplementation with cholecalciferol may provide some benefits and modulate the immunity response in airway CF patients with chronic P. aeruginosa infection reflected as reduction of the level of IL-23 in EBC.
Archives of Clinical and Biomedical Research, Volume 4, pp 302-324; doi:10.26502/acbr.50170106
Molecular pathology is continuously evolving and laboratories are challenged to implement tests accurately prior to administration of targeted therapies. External quality assessment (EQA) programs revealed method-specific problems for laboratories who switched methods, and a good adherence to guidelines during method validation/verification in the USA. This study evaluated current guideline adherence in Europe and experienced hurdles during test, marker or sample implementation. EQA participants from the European Society of Pathology were invited to complete an electronic survey if they: (i) recently changed their assay, (ii) implemented PD-L1 analysis, (iii) or introduced analysis of circulating tumor DNA. In total, survey data from 54 laboratories was analyzed. The majority of laboratories implemented a written procedure for validation (68.5%) or verification (59.3%), in 53.7% and 44.4% cases based on standards or available literature. For 20.4% of respondents, a specific guideline was not available yet for their test strategy. Method revalidations and staff training, as well as EQA participation were frequently performed. Most reported hurdles included controlling of pre-analytical variables (87.0%), finding appropriate controls for rare mutations or antigens, and for varying positivity ranges/frequency (56.5%). In the post-analytical phase, interpretation of complex bio-informatics was a main concern (70.0%), while staff limitations, increased costs and workload (53.1%-57.1%) were barriers affecting the entire test process. Documentation of procedures and guideline adherence was higher but not limited to accredited institutes. The data stressed the importance of further quality efforts to aid laboratories with controlling pre-analytical variables, the selection of appropriate controls, and test interpretation of complex data.
Archives of Clinical and Biomedical Research, Volume 4, pp 426-440; doi:10.26502/acbr.501700115
Esophageal cancer is one of the most common and lethal malignant tumors. Previous studies revealed the importance of microRNA (miRNA) and their targets in the occurrence, metastasis and prognosis of esophageal cancer. With the availability of The Cancer Genome Atlas (TCGA) database and the development of analytical tools, it is efficient and convenient to identify new biomarkers and key target genes associated with esophageal cancer prognosis through bioinformatic data mining. Five differentially expressed microRNA genes were identified to have significant association with the survival of the esophageal patients. Seven differentially expressed mRNA targets were selected to have significant association with the poor outcomes. These microRNA and mRNA genes could be the candidate biomarkers for tumor prognosis and/or therapeutic targets to improve the survival of esophageal cancer patients.
Archives of Clinical and Biomedical Research, Volume 4, pp 221-238; doi:10.26502/acbr.50170100
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and prognosis is poor despite maximum therapeutic efforts. GBM is composed of heterogeneous cell populations, among which the glioma stem-like cells (GSCs) play an important role in tumor cell self-renewal and the ability to initiate and drive tumor growth and recurrence. The transcription factor SOX2 is enriched in GSCs where it controls the stem cell phenotype, invasion and maintenance of tumorigenicity. Therefore, understanding the molecular mechanisms governed by SOX2 in GSCs is crucial to developing targeted therapies against this resistant cell population. In this study, we identified and validated a miRNA profile regulated by SOX2 in GSCs. Among these miRNAs, miR-425-5p emerged as a significant robust candidate for further study. The expression of miR- 425-5p was significantly enriched in clinical GBM specimens compared with a human brain reference sample and showed a positive correlation with SOX2 expression. Using a combination of in silico analyses and molecular approaches, we show that SOX2 binds to the promoter of miR-425-5p. Loss of function studies show that repressing miR-425-5p expression in multiple GSCs inhibited neurosphere renewal and induced cell death. More importantly, miR-425-5p inhibition extended survival in an orthotopic GBM mouse model. Finally, combining several bioinformatics platforms with biological endpoints in multiple GSC lines, we identified FOXJ3 and RAB31 as high confidence miR-425-5p target genes. Our findings show that miR-425-5p is a GBM stem cell survival factor and that miR-425-5p inhibition function is a potential strategy for treating GBM.